Should you invest in Heat Biologics (HTBX)?
What’s up with Heat Biologics?
Heat Biologics (HTBX) opened at $0.60, which means the stock is down 2.96% from yesterday’s closing price of 0.59. Today, the company has a high of $0.65 and a low of $0.56. The company has a market cap of $44.99 million with a 52-week high of $1.25 and a 52-week low of $0.20.
What about the future for Heat Biologics?
The high forecast for Heat Biologics is $5.00 while the low is $2.00. Stock forecasts are based on human experience: Human traders based on their experience in terms of stock price patterns, volume changes, and market news/rumors regarding a particular stock. Heat Biologics has a strong forecast. A strong forecast is a result of strong earning reports as investors are willing to pay a higher share price today because of growth expectations in the future. Based on this information HTBX seems to be a safe buy.
About Heat Biologics
Heat Biologics Inc. is a US biotechnology company focused on the field of cancer immunotherapy. This company’s cancer vaccine is called ImPACT, short for Immune Pan-Antigen Cytotoxic Therapy. ImPACT is in Phase II clinical trials and is being tested in NSCLC and bladder cancer.